Context: A sodium glucose cotransporter 2 (SGLT2) inhibitor, which increases urinary glucose excretion, was reported to decrease blood glucose levels and deaths among patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease. SLC5A2 and HNF1A mutations are associated with renal glycosuria, but their contributions to renal glycosuria in patients with T2DM are not well understood.
T ype 2 diabetes mellitus (T2DM) is a chronic metabolic disease that is characterized by progressive hyperglycemia, impaired insulin secretion, and insulin sensitivity. Cardiovascular disease (CVD) is a major complication of T2DM and is the leading cause of morbidity and mortality in patients with T2DM. Recently, a novel inhibitor of the sodium glucose cotransporter 2 (SGLT2) was demonstrated to effectively reduce blood glucose levels and improve hypertension and body weight control in patients with T2DM (1) by increasing their urinary glucose excretion. Moreover, a recent randomized trial showed that empagliflozin reduces the composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke in patients with T2DM and established CVD (2) . Thus, we hypothesized that in contrast to patients with T2DM and low urinary glucose excretion (LUGE), patients with T2DM and high urinary glucose excretion (for example, those with renal glycosuria) would have fewer cardiovascular risk factors, such as overweight, hypertension, and insulin resistance. In general, when blood glucose is maintained below approximately 8.9 to 10 mmol/L in healthy subjects, no glucose is present in the urine. However, when renal tubule function is compromised, urinary glucose concentrations are abnormally elevated, despite blood glucose levels remaining below 8.9 to 10 mmol/L, a condition known as renal glycosuria. Many studies have shown that renal glycosuria can be caused by genetic mutations, including mutations in SLC5A2 and HNF1A; SLC5A2 encodes SGLT2 and is a causative gene for familial glycosuria, and HNF1A accounts for maturity onset diabetes of the young type 3 (MODY3) and regulates SLC5A2 expression in renal tissue (3, 4) . Because molecular diagnostic techniques are not widely used for classifying diabetes in China, most patients with MODY3 are incorrectly diagnosed with T2DM. Thus, we also hypothesized that SLC5A2 and HNF1A mutations may partially account for renal glycosuria in Chinese patients with T2DM. To evaluate those hypotheses, we assessed the clinical features of patients with T2DM with extreme phenotypes for urinary glucose excretion and screened genetic variants of SLC5A2 and HNF1A in patients with T2DM and renal glycosuria in the current study.
Materials and Methods

Study oversight
This study was conducted in compliance with the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Peking University People's Hospital (China). Written informed consent was obtained from all study participants.
Definition of extreme phenotypes for urinary glucose excretion in patients with T2DM
In this study, we classified patients into renal glycosuria and LUGE groups. Renal glycosuria was defined as a urinary glucose concentration .5.5 mmol/L when fasting (5:30 AM) and nighttime (12:00 AM and 3:00 AM) blood glucose levels ,8 mmol/L. LUGE was defined as the absence of glycosuria when fasting and nighttime blood glucose levels greater than 10 mmol/L.
Study populations
Assessment of clinical features
A total of 2044 nonrelated hospitalized Chinese patients with T2DM were screened at the Endocrinology and Metabolism Department of Peking University People's Hospital in Beijing from April 2013 to July 2015, as indicated in the patient flowchart shown in Fig. 1 . Fifty-eight patients with T2DM and LUGE and 64 patients with T2DM and renal glycosuria were identified according to the aforementioned criteria. Diabetes was diagnosed according to the 1999 World Health Organization criteria (5) . Patients with typical clinical features of type 1 diabetes or other specific forms of diabetes (e.g., chronic pancreatitis) or those who were positive for the glutamic acid decarboxylase antibody, islet cell antibodies, and the insulin antibody were excluded from this study. Patients with red and white blood cells in their urine were also excluded.
Screening of SLC5A2 mutations
DNA samples from 32 patients with renal glycosuria were available. These samples were screened for exon variants in the SLC5A2 gene, and a novel mutation (V359G) was identified. To evaluate the prevalence of the V359G mutation of SLC5A2 in patients with T2DM and control subjects with normal glucose tolerance, 192 patients were randomly selected from the inpatient cohort, regardless of the presence of glycosuria, and 330 unrelated control subjects were selected from communities near Peking University People's Hospital, regardless of the presence of glycosuria. The inclusion criteria for the control subjects in this study were as follows: normal glucose regulation confirmed via a 75-g oral glucose tolerance test according to the 1999 World Health Organization criteria (5) (fasting plasma glucose ,6.1 mmol/L and 2-hour plasma glucose ,7.8 mmol/L), hemoglobin A1c (HbA1c) ,6%, and age $45 years.
Screening of HNF1A mutations
Because most patients with MODY3 were nonobese, 28 patients with renal glycosuria and a body mass index (BMI) ,28 kg/m 2 were selected for screening for HNF1A mutations.
Clinical characteristics
The patients' clinical information was obtained from medical records that were collected during hospitalization and included sex, age, duration of diabetes, smoking history, comorbidities, and complications. Prior medical treatment was also recorded, including the use of any antidiabetes drugs before hospitalization or on the first day of hospitalization, as well as the use of any antihypertensives or antihyperlipidemia agents. Height, weight, waist circumference, and blood pressure were measured upon initial examination on the first day of hospitalization.
Within the first 24 hours of hospitalization, nighttime capillary blood glucose levels (12:00 AM and 3:00 AM) were determined using the ACCU-CHEK Performa glucose meter (Roche Diagnostics). After an overnight fast of 10 to 12 hours, fasting venous blood (5:30 AM) was collected to measure fasting plasma glucose (FPG), total cholesterol, high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), triglycerides, creatinine, alanine aminotransferase, and aspartate aminotransferase using a Hitachi LST008 analyzer (Hitachi High-Technologies). Urinary glucose concentrations in fasting patients (5:30 AM) were determined using a semiquantitative method (Urine Analyzer, Clinitek Atlas, Siemens Healthcare Diagnostics). Fasting insulin and C-peptide levels were assessed by chemiluminescence (Roche E411; Roche Diagnostics). Roche C311 (Roche Diagnostics) was used to measure the urinary albumin/creatinine ratio.
In our study, microvascular complications included diabetic nephropathy and diabetic retinopathy, and macrovascular complications included coronary heart disease, peripheral vascular atherosclerosis, and stroke. Diabetic nephropathy was defined as a urinary albumin/creatinine ratio $30 mg/g and/or renal insufficiency. A diagnosis of diabetic retinopathy was made on the basis of the findings of direct ophthalmoscopy or fundus camera (TRC-NW100; Topcon Medical Systems) examinations or a history of laser photocoagulation therapy. Coronary heart disease was diagnosed according to the patient's medical history (presence of angina or myocardial infarctions and the results of computed tomography imaging or coronary angiography). Cerebrovascular disease was defined as a history of transient ischemic attack or ischemic or hemorrhagic stroke. Hypertension was defined as a systolic blood pressure $140 mm Hg and/or a diastolic blood pressure $90 mm Hg or current treatment of hypertension. Dyslipidemia was defined as total cholesterol $5.18 mmol/L, triglycerides $1.70 mmol/L, LDL-c $3.37 mmol/L, HDL-c ,1.3 mmol/L in women or HDL-c ,1.04 mmol/L in men, or treatment with antihyperlipidemia agents (6) . Peripheral vascular atherosclerosis was determined via ultrasonography; if plaques were detected in the carotid artery or the arteries of the lower extremities, a diagnosis of peripheral vascular atherosclerosis was made (7) . Using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) index, values were calculated as fasting insulin (mU/L) 3 fasting plasma glucose (mmol/L)/22.5, as previously described (8).
SLC5A2 and HNF1A exon sequencing
All SLC5A2 exons were amplified via polymerase chain reaction (PCR) in an Applied Biosystems 2720 Thermal Cycler with 13 pairs of oligonucleotide primers (9); and PCR conditions are shown in Supplemental Table 1 .
Ten pairs of primers (Supplemental Table 2 ) were generated to amplify all 10 HNF1A exons via PCR; the primers and the reaction conditions have been described previously (10) .
The PCR products were purified using a gel extraction kit (Axygen) and sequenced using the Sanger method on an ABI 3730xl DNA sequencer (Applied Biosystems).
High-throughput genotyping
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry was performed on the MassARRAY platform (Sequenom) to genotype the V359G mutations of SLC5A2 that were identified using Sanger sequencing. DNA samples for which genotypes were confirmed via sequencing were simultaneously genotyped as quality controls.
Statistical analysis
All statistical tests were performed using SPSS software version 22.0 for Mac (SPSS). Continuous variables are presented as the means and standard deviations (6 standard deviations) for normally distributed data or as medians (interquartile range) for nonnormally distributed data. Categorical variables are presented as numbers and percentages. Percentages were based on the number of nonmissing values. The duration of diabetes, levels of fasting serum insulin, fasting serum C-peptide, and triglycerides, and the HOMA-IR values were subjected to a natural logarithm transformation to obtain a normal distribution prior to statistical analyses. Fisher's exact tests, Student t tests, and x 2 tests were used to compare the clinical characteristics between patients with LUGE and renal glycosuria. A logistic regression analysis with a backward stepwise method was performed with renal glycosuria as the dependent variable and sex, age, BMI, hypertension, insulin therapy, and HOMA-IR as independent variables.
Results
Clinical features of patients with T2DM with different levels of urinary glucose excretion
In total, we identified 58 patients with T2DM and LUGE and 64 patients with T2DM and renal glycosuria. As shown in Table 1 , the renal glycosuria group was composed of significantly fewer female patients (P , 0.0001), as well as patients with hypertension (P = 0.006) and overweight (P = 0.027), compared with the LUGE group. FPG (P , 0.0001), age (P = 0.008), waist circumference (P = 0.012 in females), BMI (P = 0.002), and HOMA-IR (P , 0.0001) of patients with renal glycosuria were also reduced compared with those of patients with LUGE. There were no significant differences in the duration of diabetes, smoking history, dyslipidemia, coronary heart disease, cerebrovascular disease, diabetic nephropathy, diabetic retinopathy, and fasting insulin, C-peptide, HbA1c, HDL-c, LDL-c, triglycerides, and creatinine levels between the glycosuria and LUGE groups ( Table 1) . Our logistic regression analysis showed that BMI and HOMA-IR were negatively associated with renal glycosuria after adjusting for age, sex, hypertension, and insulin therapy before hospitalization (Table 2) or on the first day of hospitalization (Supplemental Table 3 ).
In addition, differences in the use of antidiabetes drugs and antihypertensives were also observed between the groups. Compared with patients with LUGE, fewer patients with renal glycosuria received insulin injections in lieu of insulin secretagogues before hospitalization and on the first day of hospitalization. Calcium channel blockers and diuretics were used less in patients with renal glycosuria and hypertension (Table 3) .
SLC5A2 exon sequencing
We screened 14 exon variants of SLC5A2 in 32 patients with renal glycosuria and identified a single mutation of glycine substituted for valine at position 359 (V359G) in exon 9 (Fig. 2) . This mutation was found in one patient and was predicted to be deleterious according to PROVEAN (http://provean.jcvi.org), SIFT (http://sift. jcvi.org), and Polyphen-2 (http://genetics.bwh.harvard. edu/pph2/). This mutation was not found in any of the 330 nondiabetic control individuals or in the National Center for Biotechnology Information Single Nucleotide Polymorphism database. In 192 patients with T2DM who were randomly selected from the inpatient cohort (regardless of the presence of glycosuria), no V359G mutations were detected. A 40-year-old male patient carrying the V359G mutation was diagnosed with T2DM four years prior and had a BMI of 28.74 kg/m 2 and normal blood pressure. He was medicated with 1500 mg/d of metformin, and his HbA1c level was 6.4%.
HNF1A exon sequencing A total of 28 patients with renal glycosuria and a BMI ,28 kg/m 2 were screened for HNF1A exon mutations. A single pathogenic mutation (R131W) in exon 2 of the HNF1A gene was identified. This mutation is listed in the Human Gene Mutation Database (http://www. hgmd.cf.ac.uk/ac/) and is a known causative mutation in diabetes (11) . The patient with this mutation was diagnosed with diabetes at 33 years old and had a BMI of 18.0 kg/m 2 and a high-sensitivity C-reactive protein (hs-CRP) level of 0.1 mg/L. His mother also carried this mutation and The b coefficients, odds ratios (95% CIs), and P values were calculated via a logistic regression model using the backward stepwise method; concomitant variables include sex, age, BMI, hypertension, insulin therapy before hospitalization, and HOMA-IR. (Table 4) .
Discussion
In the current study, we observed two clinical subtypes of T2DM that possessed differences in their clinical features. Multiple cardiovascular risk factors were found to be clustered in patients with T2DM and LUGE but not in patients with T2DM and renal glycosuria. Compared with patients with LUGE, patients with renal glycosuria were more likely to be male and were younger, on average, and they were less likely to have hypertension and had a lower BMI, smaller waist circumference (in females), and lower HOMA-IR values. HOMA-IR and BMI were negatively associated with renal glycosuria after adjusting for age, sex, hypertension, and insulin therapy. A novel rare mutation (V359G) in the SLC5A2 gene was identified in one patient with renal glycosuria and T2DM. A known mutation (R131W) in exon 2 of HNF1A was identified in one patient with a MODY-like phenotype and renal glycosuria. The factors associated with urinary glucose excretion are not well understood. Butterfield et al. (12) reported a higher prevalence of glycosuria in males than in females without hyperglycemia, as defined by oral glucose tolerance tests, and urinary glucose excretion was found to be negatively associated with age. Berthelay et al. (13) found that urinary glucose excretion decreased with obesity level, regardless of T2DM status. A recent study showed that overactivity of the sympathetic nervous system might affect urinary glucose excretion. Renal sympathetic denervation has been reported to suppress SLC5A2 overexpression in renal tissues, which led to an (14) . In fact, there is substantial evidence supporting a role of sympathetic nervous system overactivity in obesity (15) , and central obesity has been shown to have a greater association with increased sympathetic nerve activation than has been found for subcutaneous obesity (16, 17) . In the current study, compared with patients with LUGE, patients with renal glycosuria had lower insulin resistance and lower BMI levels, which may affect sympathetic nervous system activity, urinary glucose excretion, and blood pressure. Additionally, because we did not measure urinary sodium excretion in our study, we cannot exclude the possibility of increased urinary sodium excretion associated with glycosuria. Further studies are needed to elucidate the exact pathogenesis underlying the associations among obesity, insulin resistance, sympathetic nervous system overactivity, hypertension, and urinary glucose excretion in humans.
In our study, patients in the renal glycosuria group had significantly lower FPG levels compared with those in the LUGE group, which may be attributed to the fact that we assigned patients to renal glycosuria and LUGE groups according to fasting and nighttime glucose concentrations in their blood and urine. However, lower FPG levels do not completely explain our findings of fewer cardiovascular risk factors in this group, because HbA1c levels, which reflect long-term blood glucose control, were similar in both groups (9.57% vs 10.15%; P = 0.091) ( Table 1 ). This lack of a difference in HbA1c, together with lower FPG levels in the renal glycosuria group, might suggest greater glycemic variability (GV) in the renal glycosuria group; some studies have suggested that GV is a risk factor for complications (18) . Precise measurements of GV would help us to clarify its association with urinary glucose excretion and cardiovascular risk factors in future work. Moreover, as shown in Table 3 , there was a difference in the use of antidiabetes drugs (insulin therapy and insulin secretagogues) between these groups, suggesting that the differences in FPG levels and urinary glucose excretion can be attributed to the use of antidiabetes drugs. However, when we adjusted for the changes in antidiabetes drugs (insulin therapy before hospitalization or on the first day of hospitalization), the associations remained significant between BMI, HOMA-IR, and renal glycosuria. It is not surprising that hypertension and insulin therapy are not independently associated with renal glycosuria, because hypertension is associated with BMI and insulin resistance, and insulin is often required for patients with high insulin-resistance levels. Thus, BMI and insulin-resistance levels may be major factors that affect urinary glucose excretion.
No studies have been performed to evaluate the association of antihypertensives, antihyperlipidemia agents, and antidiabetes drugs on urinary glucose excretion, with the exception of studies on SGLT2 inhibitors. We found that, in the renal glycosuria group, fewer patients received insulin injections in lieu of insulin secretagogues before hospitalization; also, fewer patients in this group received three or more antidiabetes drugs on the first day of hospitalization. This observation suggests that patients with renal glycosuria had more manageable hyperglycemia compared with patients with LUGE, because physicians are more likely to administer antidiabetes drugs to patients with LUGE to achieve the target blood glucose levels recommended by clinical guidelines. Similarly, more patients with hypertension in the LUGE group used diuretics and calcium channel blockers because the combination therapy was needed to maintain adequate blood pressure control, implying that patients with LUGE and hypertension may have more severe sodium and water retention. In fact, a novel SGLT2 inhibitor also inhibits renal sodium reabsorption to reduce blood pressure (19) . However, in our study, we did not measure urinary glucose or sodium excretion via 24-hour urine collection, and further studies are needed to verify that patients with LUGE also have low sodium excretion.
Our observations that patients with T2DM with renal glycosuria had a lower BMI, lower blood pressure, and less insulin resistance are consistent with the predicted effects of an SGLT2 inhibitor (19, 20) . These findings also suggest that there are subtypes of T2DM that are characterized by different patterns of urinary glucose excretion and cardiovascular risk factors. Recently, Zinman et al. (2) found that empagliflozin, acting as an SGLT2 inhibitor, reduced the composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke compared with the effects of a placebo in patients with T2DM with established CVD. These data indicate that patients with T2DM with renal glycosuria are at a lower risk of CVD than patients with LUGE. Unfortunately, empagliflozin-treated patients with T2DM may have a high risk of genital infections (2) . Therefore, patients with LUGE and T2DM would benefit more from an SGLT2 inhibitor and would likely be more willing to accept a low risk of genital infection than patients with renal glycosuria. It would be interesting to evaluate the outcomes of SGLT2 inhibitor treatment in patients with T2DM with LUGE and renal glycosuria in future studies.
A few genes have been reported to affect urinary glucose excretion. HNF1A is an activating transcription factor that upregulates the expression of the insulin gene in islet b cells, hs-CRP in the liver, and SLC5A2 in renal tissues (21) . Thus, mutations in the HNF1A gene can lead to MODY3, which is characterized by impaired insulin secretion, a relatively low body weight, low hs-CRP levels, and glycosuria (22) , which is in accordance with our observations. Notably, R131W of HNF1A, identified in our study, was previously confirmed to cause MODY3 (11); both the proband and his mother were diagnosed with diabetes before 40 years of age and carried the same mutation. Therefore, for patients with early-onset diabetes, renal glycosuria, and low hs-CRP levels, screening for HNF1A mutations is warranted to determine the best treatment options.
It is widely accepted that familial renal glycosuria can be inherited in an autosomal recessive or autosomal dominant manner. Individuals with one mutation of the SLC5A2 gene typically have a milder phenotype than those with two mutations (OMIM:182381). In the current study, one novel rare mutation (V359G) of SLC5A2 was identified in a patient diagnosed four years prior with T2DM who was treated with 1.5 g/d of metformin and had normal blood pressure and satisfactory blood glucose control. Thus, we inferred that hyperglycemia in patients who have diabetes with SLC5A2 mutations may be easily controlled, although these observations require confirmation in future large-scale studies.
There are some limitations to our study. First, because of the nature of a cross-sectional study, we were unable to establish a causal relationship between cardiovascular risk factors and urinary glucose excretion. Second, because the examinations in our study were conducted on a single urine sample on only one day using a semiquantitative method, it was difficult to accurately determine whether renal glycosuria or LUGE was present in patients with glycosuria and FPG levels greater than 8 to 10 mmol/L and in patients without glycosuria and FPG concentrations less than 8 to 10 mmol/L. Because 8.9 to 10 mmol/L is generally accepted as the normal range for the renal glucose threshold, and there can be random errors in blood glucose measurements, patients with FPG levels ranging from 8 to 10 mmol/L were difficult to correctly classify. Thus, only 122 patients met the inclusion criteria in this study; a future study with a larger sample size is needed. Third, our results may be affected by confounding variables, such as GV and medications. A stratified analysis in a larger patient population is needed to confirm our findings.
Conclusion
In summary, there are two subtypes of T2DM that are characterized by different urinary glucose excretion patterns and cardiovascular risk factors. Fewer cardiovascular risk factors, such as overweight and hypertension, appear in patients with T2DM with renal glycosuria compared with those with LUGE. Mutations in SLC5A2 and HNF1A partially explain renal glycosuria in patients with T2DM. SGLT2 inhibitors may be more effective for patients with LUGE than for those with renal glycosuria. Further studies are needed to confirm our findings.
